GlycoEra

Precision protein degradation to stop autoimmune disease at the source

Wädenswil, Switzerland · $179.0M raised

Headquarters
Wädenswil
Employees
11–50
Business Model
B2B
Total Funding
$179.0M
Last Round
$130.0M Series BMay 2025
Rounds
3

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

GlycoEra AG is a Swiss biotechnology company developing precision protein-degrading biologics to treat autoimmune diseases at their root cause. Headquartered on the Tuwag-Areal in Wädenswil, Switzerland, GlycoEra's platform selectively degrades specific circulating autoantibodies rapidly and deeply without broad immune suppression, enabling earlier disease intervention. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies implicated in a range of autoimmune diseases. The company raised a $130 million Series B led by Novo Holdings in 2025 to advance GE8820 through clinical proof-of-concept.

Summary

GlycoEra is a Biotech company based in Wädenswil, Switzerland. It has raised $179.0M in total across 3 rounds, most recently a $130.0M Series B round in May 2025. Investors include Sofinnova Partners, 5AM Ventures and Roche.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BMay 2025
$130.0M

Sign up to see all 3 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

GlycoEra on Indexed.vc
<a href="https://indexed.vc/companies/glycoera"><img src="https://indexed.vc/api/badge/company/glycoera" alt="GlycoEra on Indexed.vc" width="260" height="76" /></a>